Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational StudyBNT162b2 COVID-19 백신의 3차 접종에 대한 세포 및 체액 면역 반응 - 전향적 관찰 연구Observational Study Published on 2022-07-012022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] addition administration All participant All participants anti-SARS-CoV-2 antibody binding binding antibody blood sample Blood samples BNT162b2 booster booster dose cellular Cellular immune response Combination COVID-19 detectable dose evaluate health-care humoral humoral and cellular immunity Humoral immunity immune response Immunity immunological infection rate infection rates interferon Interferon-gamma median Neutralizing antibodies neutralizing antibody observational study of BNT162b2 participant peptide peptides prime-boost regimen Prospective prospective observational study protocols provided quantitative assay questionnaire Questionnaires real-world data response SARS-CoV-2 second dose Seroprevalence significant increase significantly third dose vaccination Vaccine was measured were measured [DOI] 10.3389/fimmu.2022.896151 PMC 바로가기 [Article Type] Observational Study
Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studiesSARS-CoV-2 백신 3차 접종: 30건의 발표된 연구에 대한 체계적인 검토Article Published on 2022-06-012022-09-12 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] analyzed Anti-spike article booster Cancer conducted conversion rate COVID-19 COVID-19 infection COVID-19 vaccine death dose doses Efficacy and safety English language expressed General population IgG Immunocompromised patients Patient pooled rate PROTECT ranged reduction in returned risk risk of infection SARS-CoV-2 selected Seroconversion severe disease subjects systematic review third dose vaccination [DOI] 10.1002/jmv.27644 PMC 바로가기 [Article Type] Article
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies림프성 악성종양 환자에서 BNT162b2 mRNA 백신 2회 및 3회 투여 후 항-SARS-CoV-2 항체 반응Article Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] affected anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD38 anti-RBD Anti-RBD IgG antibody antibody concentration Antibody concentrations Antibody Response B-cell malignancies B-cell malignancy benefit binding domain booster Cell Cohort Concentration conducted Course COVID-19 COVID-19 patient COVID-19 patients disorders dose effective evaluate haematological malignancies haematological malignancy Haematologicalmalignancies humoral Humoral response humoral responses IgG Immunocompromised increment IQR lymphoid lymphomas malignancies malignancy median monoclonal Mortality mRNA vaccination mRNA vaccine of BNT162b2 Patient patients patients treated plasma Plasma cell Prophylaxis quantification RBD SARS-CoV-2 Seroconversion seroconversion rate seroconverted serological serological response serology significantly spike the disease the vaccine therapy third dose Vaccine vaccine dose [DOI] 10.1016/j.cmi.2022.02.029 PMC 바로가기 [Article Type] Article
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial영국에서 ChAdOx1 nCov-19 또는 BNT162b2 2회 접종 후 3차 추가 접종으로 7가지 COVID-19 백신을 투여한 후 면역원성의 지속성: COV-BOOST 시험의 3개월 분석Clinical Trial Published on 2022-06-012022-09-11 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, [키워드] Ad26 Ad26.COV2.S adenoviral vector adenoviral vector vaccine Analysis anti-Spike IgG antibody AstraZeneca BNT BNT162b2 booster booster dose cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Concentration conducted COV-BOOST COVID-19 COVID-19 vaccine Critical death dose doses evaluate Fractional dose geometric mean geometric mean concentration geometric mean ratio GMR GMRs Heterologous boost highest Homologous boost humoral Humoral response immune response immune responses immunogenicity initial janssen long-lasting maintenance median age mRNA mRNA vaccine mRNA vaccines multicentre naïve no significant difference Oxford-AstraZeneca participant persistence Pfizer-BioNTech Phase 2 phase 2 trial randomised referred to response responses SARS-CoV-2 Seven severe disease significant difference significantly higher the vaccine third dose Transmission Trial Vaccine Vaccines variants of concern while [DOI] 10.1016/j.jinf.2022.04.018 PMC 바로가기 [Article Type] Clinical Trial
The effect of a third BNT162b2 vaccine on breakthrough infections in health care workers: a cohort analysis의료 종사자의 돌발성 감염에 대한 세 번째 BNT162b2 백신의 효과: 코호트 분석Article Published on 2022-05-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 all age groups BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine booster booster dose Breakthrough infection breakthrough infections Care Cohort cohort analysis coronavirus coronavirus disease Coronavirus disease 2019 defined delta variant dose follow-up period HCW HCWs Health Health care Health care worker health care workers indicate infection rate infection rates infections initiated Jerusalem mass vaccination Ministry of Health protective effect Relative risk risk SARS-CoV-2 severe acute respiratory syndrome Coronavirus significantly lower third dose two-dose regimen vaccination Vaccine vaccine dose variant [DOI] 10.1016/j.cmi.2022.01.019 PMC 바로가기 [Article Type] Article
Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies고효율 요법으로 치료받는 다발성 경화증 환자에서 항-SARS-CoV-2 백신의 추가 용량 후 체액 반응Article Published on 2022-05-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Anti-RBD IgG anti-SARS-CoV-2 Anti-SARS-Cov2 vaccine antibody binding domain booster booster dose disease dose Efficacy evaluated Humoral response IgG management mRNA vaccine Multiple multiple sclerosis patients treated RBD receiving Result Seroconversion significant increase Therapies therapy third dose vaccination Vaccine [DOI] 10.1016/j.msard.2022.103776 PMC 바로가기 [Article Type] Article
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study활성 치료 중인 고형 종양 환자에서 BNT162b2 항-SARS-CoV-2 백신 3차 접종 후 면역원성과 안전성: 전향적 코호트 연구Article Published on 2022-04-012022-09-11 Journal: ESMO open [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] active treatment acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration anti-SARS-CoV-2 antibody baseline BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine booster booster dose Cancer cancer patient Cancer patients cell-mediated immune cell-mediated immune response Concentration consecutive patient coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 COVID-19 infection Delta dose effective Efficacy enrolled evaluated Gamma humoral IgG IgG antibody immunogenicity Immunoglobulin Immunoglobulin G interferon interferon gamma interferon-γ interquartile range IQR median Messenger RNA naïve naïve subject naïve subjects neutralization Neutralizing neutralizing antibody of BNT162b2 omicron Patient patients Preliminary data primary endpoint prospective cohort study quantified reached recruited Release respiratory SARS-CoV-2 SARS-CoV-2 vaccine serum severe acute respiratory syndrome Coronavirus significantly higher solid cancer solid tumor subject subjects the median the SARS-CoV-2 third dose Treatment Trigger Vaccine variant variants variants of concern VOCs were used whole blood sample wild-type strain [DOI] 10.1016/j.esmoop.2022.100458 PMC 바로가기 [Article Type] Article
Booster or additional vaccination doses in patients vaccinated against COVID-19COVID-19 예방 접종을 받은 환자의 추가 접종 또는 추가 접종Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 변종, [키워드] accelerate additional doses administer Administered administration adverse effect asked booster booster dose college Committee Consensus COVID COVID-19 COVID-19 vaccine criteria decrease deliberation dose doubt Efficacy English form group Health Health Organization higher risk immunocompromised individual immunocompromised individuals incompatible individual information Laboratory tests lack less lower risk moment mRNA mRNA vaccines observation period organizations Patient physician Population population groups question reduce risk SARS-CoV-2 Spanish spur the disease the vaccine third dose vaccinated against COVID-19 vaccination Vaccines variant virus World Health Organization [DOI] 10.37201/req/149.2021 PMC 바로가기 [Article Type] Review
SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Should We Consider Intradermal Vaccination?Comment Published on 2022-04-012023-07-08 Journal: Journal of the American Society of Nephrology : JA [Category] COVID19(2023년), [키워드] COVID-19 COVID-19 vaccines intradermal vaccination kidney transplant recipients SARS-CoV-2 T lymphocytes third dose [DOI] 10.1681/ASN.2021121566 PMC 바로가기 [Article Type] Comment
Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant동종이식 후 BNT162b2 anti-SARS-CoV-2 메신저 RNA 백신 3차 접종에 대한 관심Article Published on 2022-03-012022-09-12 Journal: British Journal of Haematology [Category] MERS, SARS, 진단, [키워드] Abstract acute respiratory syndrome Allogeneic allogeneic haematopoietic stem cell transplantation anti-SARS-CoV-2 BNT162b2 Cell coronavirus disease Coronavirus disease 2019 (COVID-19) Coronavirus-2 dose interest Messenger RNA of BNT162b2 SARS-CoV-2 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA third dose Vaccine [DOI] 10.1111/bjh.17911 PMC 바로가기 [Article Type] Article